Sionna
PublicSionna is now publicly traded
The data on this page reflects Sionna's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 7, 2025
Last Round
Series C
Mar 6, 2024
Total Funding Raised
$551.2M
Company Overview
Sionna is a life sciences company specializing in the development of innovative treatments for cystic fibrosis through first-in-class small molecules aimed at fully normalizing CFTR function for the majority of patients.
Sector
Healthcare/Wellness
AI Layer
Non-AI
Keywords
Sionna Comparables
Compare Sionna with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enterprise Therapeutics | 64% | |
| ReCode Therapeutics | 64% | |
| cystetic Medicines | 60% |
Sionna Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 7, 2025 | ||||
| Series C | Mar 6, 2024 | ||||
| Series B | Apr 19, 2022 | ||||
| Series A | Aug 1, 2019 |
Sionna Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series C |
| Q Healthcare Holdings, LLC. | Series C, Series B |
| RA Capital Advisors | Series C, Series B |
| RA Capital Management | Series C, Series B, Series A |
| Perceptive Advisors | Series C, Series B |
| Guggenheim Securities | IPO |
| Altitude Life Science Ventures | Series C |
Sionna Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access